Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 4Ovarian Neoplasms 2Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 27Cyclophosphamide 14Gemcitabine 13fludarabine 11Carboplatin 10aldesleukin 9Trastuzumab 9Specimen Handling 9Nivolumab 9Magnetic Resonance Spectroscopy 8Biopsy 8olaparib 7Cisplatin 7Paclitaxel 6palbociclib 5atezolizumab 5Taxes 5Early Intervention, Educational 5Oxaliplatin 4Methods 4Irinotecan 4Drug Therapy 4Docetaxel 4Cetuximab 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4talazoparib 3spartalizumab 3pertuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × gedatolisib × Gynecologic × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡